Loading patent…
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsMinnie M. Sarwal, Tara Sigdel, Amit Kaushal, Li Li, Wenzhong Xiao, Atul J. Butte, Purvesh Khatri
Estimating the term…
Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.
A method of detecting transplant rejection in a solid organ transplant recipient, the method comprising:
A method of treating a solid organ transplant recipient, the method comprising increasing immunosuppressive therapy to the recipient when the recipient has a gene expression profile indicating that the recipient is undergoing transplant rejection, wherein increased expression levels of each of the genes EPOR, GZMK, RARA, RXRA, SLC25A37, CFLAR, NKTR, PSEN1, ITGAX, DUSP1, RYBP, MAPK9, and NAMPT over normal expression levels of each of the genes is indicative of transplant rejection in recipient.
Dependencies are inferred from the claim text.